MedTrace Logo

Zidovudine Levels in HIV Infected Patients Being Treated for HCV

NCT00059358 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-08-07

No results posted yet for this study

Summary

This study will test the amount of anti-HIV drugs in the blood cells of HIV-infected patients who are also being treated for hepatitis C virus (HCV) infection.

Conditions

  • HIV Infections
  • Hepatitis C

Interventions

DRUG

Ribavirin plus interferon alfa-2b

Oral tablets taken daily

DRUG

Ribavirin

Oral tablet taken daily

DRUG

Peginterferon alfa-2b

Subcutaneous injection

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Jose F. Rodriguez, PhD · MSC-UPR

  • Jorge L. Santana, MD · MSC-UPR

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00059358 on ClinicalTrials.gov